Finance

Lists
532488:BOM
Divi's Laboratories Ltd
9 220,00 INR
+1,99%
(+180,05) 1D
16-окт., 15:56:15 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 532488...
Open
9 013,35 INR
High
9 247,50 INR
Low
8 985,00 INR
Mkt. cap
2,45 трлн
Avg. vol.
33,69 миң
Volume
17,22 миң
Dividend
0,33%
Quarterly dividend
7,50 INR
Ex-dividend date
2026-ж., 24-июл.
P/E ratio
83,67
52-wk high
10 000,00 INR
52-wk low
5 648,00 INR
EPS
110,20 INR
Shares outstanding
265,47 млн
No. of employees
12 миң
Open
9 013,35 INR
High
9 247,50 INR
Low
8 985,00 INR
Mkt. cap
2,45 трлн
Avg. vol.
33,69 миң
Volume
17,22 миң
Dividend
0,33%
Quarterly dividend
7,50 INR
Ex-dividend date
2026-ж., 24-июл.
P/E ratio
83,67
52-wk high
10 000,00 INR
52-wk low
5 648,00 INR
EPS
110,20 INR
Shares outstanding
265,47 млн
No. of employees
12 миң
News stories
From web sources and news partners
Profile
Divi's Laboratories Limited is an Indian multinational pharmaceutical company and producer of active pharmaceutical ingredients and intermediates, headquartered in Hyderabad. The company manufactures and custom synthesizes generic APIs, intermediates. The company also manufactures and supplies nutraceutical ingredients through its subsidiary, Divi's Nutraceuticals. Divi's Laboratories is India's fourth largest publicly listed pharmaceutical company by market capitalization. Wikipedia
About Divi's Laboratories Ltd
CEOKiran S. Divi
Employees11,6 миң
Founded1990-ж., 12-окт.
Headquarters-
SectorHealth care
Last report
2026-ж., 1-авг.
Fiscal period
Q1 2027
33,95 INR / 24,68 INR
+37,58%beat
Revenue / Est. (INR)
30,80 млд / 27,61 млд
+11,56%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
27,15 млд
26,04 млд
28,31 млд
30,80 млд
Cost of goods sold
10,73 млд
9,45 млд
13,49 млд
9,86 млд
Cost of revenue
10,73 млд
9,45 млд
13,49 млд
9,86 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,54 млд
3,67 млд
3,99 млд
4,08 млд
Operating expense
8,67 млд
8,87 млд
6,68 млд
9,65 млд
Total operating expenses
19,40 млд
18,32 млд
20,17 млд
19,51 млд
Operating income
7,75 млд
7,72 млд
8,14 млд
11,29 млд
Other non operating income
820,00 млн
690,00 млн
-2,23 млд
640,00 млн
EBT including unusual items
9,12 млд
7,80 млд
9,63 млд
11,80 млд
EBT excluding unusual items
9,12 млд
8,54 млд
9,59 млд
11,80 млд
Income tax expense
2,23 млд
1,97 млд
2,12 млд
2,78 млд
Effective tax rate
24,45%
25,26%
22,01%
23,56%
Other operating expenses
4,00 млд
4,02 млд
1,49 млд
4,24 млд
Net income
6,89 млд
5,83 млд
7,51 млд
9,02 млд
Net profit margin
25,38%
22,39%
26,53%
29,29%
Earnings per share
25,97
24,07
28,31
33,95
Interest and investment income
-
-
2,84 млд
-
Interest expense
-80,00 млн
-60,00 млн
-60,00 млн
-60,00 млн
Net interest expenses
-80,00 млн
-60,00 млн
2,78 млд
-60,00 млн
Depreciation and amortization charges
1,13 млд
1,18 млд
1,20 млд
1,33 млд
EBITDA
8,88 млд
8,72 млд
9,29 млд
12,44 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору